Premium
Primary Cutaneous Follicle Center Cell Lymphoma of the Scalp Successfully Treated with Anti CD20 Monoclonal Antibody and CHOP Combination Therapy with No Subsequent Permanent Loss of Hair
Author(s) -
Imai Yasutomo,
Isoda Kenichi,
Ito Emiko,
Hakamada Arata,
Yamanishi Kiyofumi,
Mizutani Hitoshi
Publication year - 2003
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.2003.tb00458.x
Subject(s) - rituximab , scalp , medicine , cd20 , chop , lymphoma , hair loss , cd5 , monoclonal antibody , hair follicle , asymptomatic , monoclonal antibody therapy , pathology , antibody , dermatology , immunology
We present a primary cutaneous follicle center cell lymphoma (PCFCCL) patient who was successfully treated with Rituximab, a new anti‐CD20 monoclonal antibody. A thirty‐two‐year‐old male developed two asymptomatic tumors on the scalp. Histopathologically, the tumors were composed of diffuse and nodular infiltration of centrocytes and centroblasts. Immunohistopathologically, the tumor cells stained positively with anti‐CD20 antibody and anti‐kappa antibody, but not with anti‐CD5, anti‐CD10, or anti‐Bcl‐2 antibody. Radiation therapy is effective in treating PCFCCL; however, it usually results in the permanent loss of hair. This patient was treated with Rituximab and CHOP, and achieved a complete remission. He has had no recurrence in more than 12 months and no permanent loss of hair on the scalp.